Lymphocytes, Monocytes, and CD34+ Cells in Unmanipulated Apheresis Products and After CD34+ FACS Isolation
| . | Apheresis Product From Control Patients . | Apheresis Product From Sort Patients . | FACS-Enriched CD34+PBSC . |
|---|---|---|---|
| T cells | 17 ± 6 | 56 ± 32 | .0037 ± .005 |
| Monocytes | 47 ± 49 | 407 ± 172 | .001 ± .001 |
| B cells | 2 ± 2 | 3 ± 3 | .0024 ± .005 |
| CD34+ cells | 8 ± 4 | 36 ± 31 | 1.8 ± .8 |
| . | Apheresis Product From Control Patients . | Apheresis Product From Sort Patients . | FACS-Enriched CD34+PBSC . |
|---|---|---|---|
| T cells | 17 ± 6 | 56 ± 32 | .0037 ± .005 |
| Monocytes | 47 ± 49 | 407 ± 172 | .001 ± .001 |
| B cells | 2 ± 2 | 3 ± 3 | .0024 ± .005 |
| CD34+ cells | 8 ± 4 | 36 ± 31 | 1.8 ± .8 |
The mean number (±SD) of T cells, B cells, monocytes, and CD34+ cells/kg (×106) in the apheresis products form a group of control patients with lymphoid malignancies (n = 4), the group of study patients undergoing apheresis before CD34+ cells selection (n = 9), and the PBSC product following CD34+ cell selection and FACS isolation (n = 9) were determined by flow cytometry. The volume of apheresis performed on the study patients was larger than that performed on the group of control patients.